Close
CDMO Safety Testing 2026
Novotech

New potential drug targets discovered for preventing prostate cancer cell growth

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

CMS Extends GENEROUS MFN Drug Pricing Deadline to April

The Centers for Medicare & Medicaid Services (CMS) in...

How APAC Biotech Plans to Turn 2026 Trends into Innovation While Managing Risk?

Asia-Pacificโ€™s biotechnology landscape is not just growing it is...
- Advertisement -

Researchers from VTT Technical Research Centre of Finland and the University of Turku have discovered four metabolic enzymes regulating prostate cancer cell growth. Inhibition of these enzymes prevents prostate cancer cell growth in cultured cells. This knowledge can be used to identify different subtypes of prostate cancer and for designing targeted therapies for prostate cancer.

Eicosanoid hormones, which are metabolites of arachidonic acid found in animal-based foods, such as eggs and meat, are essential regulators of normal bodily functions. Metabolic dysfunction relating to these bioactive lipids plays a role in many diseases. Prostate cancer cells use increased arachidonic acid metabolism and eicosanoid production to fuel their enhanced growth.

In addition to previously discovered enzymes that contribute to prostate cancer cell growth, the new study published by researchers from VTT and the University of Turku identifies four enzymes that regulate arachidonic acid metabolism and reveals that prostate cancer cell growth can be inhibited by preventing the functioning of these enzymes.

The study analysed the prevalence of enzymes involved in arachidonic acid metabolism in hundreds of prostate cancer samples, normal prostate samples, and other healthy tissues. The enzymes with the highest expression in prostate cancer samples were selected for further studies in prostate cancer cells. The scientists discovered that certain enzymes were more prevalent than others in different kinds of prostate cancers. This knowledge can be used to identify different subtypes of prostate cancer in the future. The findings of the study provide valuable new information and can potentially lead to the discovery of new ways to treat prostate cancer.

The findings relating to the prevalence and effects of enzymes involved in arachidonic acid metabolism were published in The American Journal of Pathology in February 2011 (Arachidonic Acid Pathway Members PLA2G7, HPGD, EPHX2, and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer. The American Journal of Pathology, Volume 178, Issue 2, Pages 525โ€“536, February 2011)

ย 

World Pharma Today brings together the global pharmaceutical industry โ€” from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives โ€” through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

CMS Extends GENEROUS MFN Drug Pricing Deadline to April

The Centers for Medicare & Medicaid Services (CMS) in...

How APAC Biotech Plans to Turn 2026 Trends into Innovation While Managing Risk?

Asia-Pacificโ€™s biotechnology landscape is not just growing it is...

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป